FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885381685> ?p ?o ?g. }

• W2885381685 endingPage "3823" @default.
• W2885381685 startingPage "3823" @default.
• W2885381685 abstract "Abstract Depletion of malignant B cells using anti-CD20 antibodies is one of the most effective approaches for CD20-positive non-Hodgkin lymphoma therapy. Anti-CD20 antibodies can activate several pathways including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or programmed cell death to kill tumor cells. ADCC is mediated via Fc region of antibody binding to FcγRIIIa receptor on effector cells, such as NK cells. Previous studies have shown that non-fucosylated antibody binds to FcγRIIIa with increased affinity and can thus trigger FcγRIIIa-mediated effector functions more efficiently than native, fucosylated antibody. Obinutuzumab, an FDA-approved anti-CD20 antibody with approximate 30% fucose level of a normal antibody, has demonstrated better efficacy than fucosylated rituximab. We generated BAT4306F, which has the same sequence as obinutuzumab yet is completely devoid of fucose modification. BAT4306F induced higher level of ADCC effect compared with rituximab and obinutuzumab in vitro. BAT4306F also showed significantly superior activity on depleting B cells in whole blood compared to rituximab, and superior activity compared to obinutuzumab. In monkeys dosed once with these antibodies, BAT4306F demonstrated much stronger B-cell depletion activity than that of obinutuzumab and rituximab, whether detected in serum, spleen, or lymph node. The residual B cells detected in spleen of monkey treated with BAT4306F were 8-fold less than that of obinutuzumab, and 10-fold less than that of rituximab. Furthermore, BAT4306F demonstrated stronger tumor-inhibition activity than rituximab in a DLBCL tumor cell xenograft mouse model. Preclinical acute and long-term toxicity studies in monkey reveal that BAT4306F is well tolerated. Together these data demonstrate that BAT4306F is more potent than obinutuzumab and rituximab due to a complete defucosylation. The result warrants further clinical development of BAT4306F. Citation Format: Jin-Chen Yu, Chao Qin, Shengfeng Li. Bat4306f, an anti-CD20 antibody devoid of fucose modification, demonstrates enhanced ADCC effect and potent in vivo efficacy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3823." @default.
• W2885381685 created "2018-08-22" @default.
• W2885381685 creator A5014900922 @default.
• W2885381685 creator A5057736963 @default.
• W2885381685 creator A5063918608 @default.
• W2885381685 date "2018-07-01" @default.
• W2885381685 modified "2023-10-16" @default.
• W2885381685 title "Abstract 3823: Bat4306f, an anti-CD20 antibody devoid of fucose modification, demonstrates enhanced ADCC effect and potent in vivo efficacy" @default.
• W2885381685 doi "https://doi.org/10.1158/1538-7445.am2018-3823" @default.
• W2885381685 hasPublicationYear "2018" @default.
• W2885381685 type Work @default.
• W2885381685 sameAs 2885381685 @default.
• W2885381685 citedByCount "1" @default.
• W2885381685 countsByYear W28853816852023 @default.
• W2885381685 crossrefType "journal-article" @default.
• W2885381685 hasAuthorship W2885381685A5014900922 @default.
• W2885381685 hasAuthorship W2885381685A5057736963 @default.
• W2885381685 hasAuthorship W2885381685A5063918608 @default.
• W2885381685 hasConcept C109316439 @default.
• W2885381685 hasConcept C159654299 @default.
• W2885381685 hasConcept C18031839 @default.
• W2885381685 hasConcept C185592680 @default.
• W2885381685 hasConcept C202751555 @default.
• W2885381685 hasConcept C203014093 @default.
• W2885381685 hasConcept C2777607594 @default.
• W2885381685 hasConcept C2780653079 @default.
• W2885381685 hasConcept C40677261 @default.
• W2885381685 hasConcept C502942594 @default.
• W2885381685 hasConcept C542903549 @default.
• W2885381685 hasConcept C55493867 @default.
• W2885381685 hasConcept C71924100 @default.
• W2885381685 hasConceptScore W2885381685C109316439 @default.
• W2885381685 hasConceptScore W2885381685C159654299 @default.
• W2885381685 hasConceptScore W2885381685C18031839 @default.
• W2885381685 hasConceptScore W2885381685C185592680 @default.
• W2885381685 hasConceptScore W2885381685C202751555 @default.
• W2885381685 hasConceptScore W2885381685C203014093 @default.
• W2885381685 hasConceptScore W2885381685C2777607594 @default.
• W2885381685 hasConceptScore W2885381685C2780653079 @default.
• W2885381685 hasConceptScore W2885381685C40677261 @default.
• W2885381685 hasConceptScore W2885381685C502942594 @default.
• W2885381685 hasConceptScore W2885381685C542903549 @default.
• W2885381685 hasConceptScore W2885381685C55493867 @default.
• W2885381685 hasConceptScore W2885381685C71924100 @default.
• W2885381685 hasIssue "13_Supplement" @default.
• W2885381685 hasLocation W28853816851 @default.
• W2885381685 hasOpenAccess W2885381685 @default.
• W2885381685 hasPrimaryLocation W28853816851 @default.
• W2885381685 hasRelatedWork W1938144043 @default.
• W2885381685 hasRelatedWork W2000365588 @default.
• W2885381685 hasRelatedWork W2043202786 @default.
• W2885381685 hasRelatedWork W2090404922 @default.
• W2885381685 hasRelatedWork W2135802989 @default.
• W2885381685 hasRelatedWork W2136385642 @default.
• W2885381685 hasRelatedWork W2322176051 @default.
• W2885381685 hasRelatedWork W2580497094 @default.
• W2885381685 hasRelatedWork W2921656272 @default.
• W2885381685 hasRelatedWork W4362478588 @default.
• W2885381685 hasVolume "78" @default.
• W2885381685 isParatext "false" @default.
• W2885381685 isRetracted "false" @default.
• W2885381685 magId "2885381685" @default.
• W2885381685 workType "article" @default.